2-Methyl-7-[3-(4-phenoxy-2-propyl-phenoxy)-propoxy]-chroman-2-carboxylic acid | 717901-08-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-Methyl-7-[3-(4-phenoxy-2-propyl-phenoxy)-propoxy]-chroman-2-carboxylic acid
• 英文别名: 2-methyl-7-[3-(4-phenoxy-2-propylphenoxy)propoxy]-3,4-dihydrochromene-2-carboxylic acid
• CAS: 717901-08-1
• 化学式: C₂₉H₃₂O₆
• 分子量: 476.569
• InChiKey: REPLEBPTHZQCFG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7
• 重原子数：
  35
• 可旋转键数：
  11
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.34
• 拓扑面积：
  74.2
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  1-(3-溴丙氧基)-4-苯氧基-2-丙基苯 在 sodium hydroxide 、 caesium carbonate 作用下， 以 N,N-二甲基甲酰胺 、 异丙醇 为溶剂， 反应 5.0h， 生成 2-Methyl-7-[3-(4-phenoxy-2-propyl-phenoxy)-propoxy]-chroman-2-carboxylic acid
  参考文献：
  名称：

  (2R)-2-Ethylchromane-2-carboxylic Acids:  Discovery of Novel PPARα/γ Dual Agonists as Antihyperglycemic and Hypolipidemic Agents

  摘要：

  A series of chromane-2-carboxylic acid derivatives was synthesized and evaluated for PPAR agonist activities. A structure-activity relationship was developed toward PPARalpha/gamma dual agonism. As a result, (2R)-7-{3-[2-chloro-4-(4-fluorophenoxy)phenoxy]propoxy}-2-ethylchromane-2-carboxylic acid (48) was identified as a potent, structurally novel, selective PPARalpha/gamma dual agonist. Compound 48 exhibited substantial antihyperglycemic and hypolipidemic activities when orally administered in three different animal models: the db/db mouse type 2 diabetes model, a Syrian hamster lipid model, and a dog lipid model.

  DOI：

  10.1021/jm030621d

文献信息

• (2<i>R</i>)-2-Ethylchromane-2-carboxylic Acids:  Discovery of Novel PPARα/γ Dual Agonists as Antihyperglycemic and Hypolipidemic Agents
  作者：Hiroo Koyama、Daniel J. Miller、Julia K. Boueres、Ranjit C. Desai、A. Brian Jones、Joel P. Berger、Karen L. MacNaul、Linda J. Kelly、Thomas W. Doebber、Margaret S. Wu、Gaochao Zhou、Pei-ran Wang、Marc C. Ippolito、Yu-Sheng Chao、Arun K. Agrawal、Ronald Franklin、James V. Heck、Samuel D. Wright、David E. Moller、Soumya P. Sahoo

  DOI：10.1021/jm030621d

  日期：2004.6.1

  A series of chromane-2-carboxylic acid derivatives was synthesized and evaluated for PPAR agonist activities. A structure-activity relationship was developed toward PPARalpha/gamma dual agonism. As a result, (2R)-7-3-[2-chloro-4-(4-fluorophenoxy)phenoxy]propoxy}-2-ethylchromane-2-carboxylic acid (48) was identified as a potent, structurally novel, selective PPARalpha/gamma dual agonist. Compound 48 exhibited substantial antihyperglycemic and hypolipidemic activities when orally administered in three different animal models: the db/db mouse type 2 diabetes model, a Syrian hamster lipid model, and a dog lipid model.